Viridian Therapeutics, Inc.
VRDN
$19.23
$1.216.69%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -50.87% | -41.35% | -13.55% | -18.66% | -15.24% |
| Total Depreciation and Amortization | -13.78% | -11.01% | -6.20% | 46.72% | 1,344.21% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -44.05% | -53.61% | -56.55% | 1.24% | 38.21% |
| Change in Net Operating Assets | -29.40% | 108.63% | 201.84% | 289.54% | 1,085.04% |
| Cash from Operations | -83.68% | -67.09% | -26.14% | -9.31% | -3.93% |
| Capital Expenditure | 3.78% | 23.75% | 43.10% | 58.83% | 27.98% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 114.21% | 106.74% | -144.38% | -221.92% | -84.20% |
| Cash from Investing | 113.91% | 106.45% | -142.60% | -219.04% | -83.42% |
| Total Debt Issued | -- | -- | -- | -100.00% | 3,263.23% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -12.69% | -13.62% | 213.15% | 1,322.54% | 5.52% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -67.19% | -67.19% | -67.19% | -- | 73.16% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 26.87% | 26.09% | -118.77% | -1,884.78% | -1.26% |
| Cash from Financing | -25.81% | -26.53% | 102.83% | 1,077.70% | 19.31% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -53.09% | 686.12% | 93.87% | 138.14% | -63.10% |